;PMID: 8696774
;source_file_987.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:41..169] = [t:41..169]
;2)section:[e:173..240] = [t:173..240]
;3)section:[e:244..334] = [t:244..334]
;4)sentence:[e:338..519] = [t:338..519]
;5)sentence:[e:520..767] = [t:520..767]
;6)sentence:[e:768..948] = [t:768..948]
;7)sentence:[e:949..1142] = [t:949..1142]
;8)sentence:[e:1143..1247] = [t:1143..1247]
;9)sentence:[e:1248..1369] = [t:1248..1369]
;10)sentence:[e:1370..1617] = [t:1370..1617]
;11)section:[e:1621..1665] = [t:1621..1665]

;section 0 Span:0..35
;Chemosphere. 1996 Jul;33(2):265-76.
(SEC
  (FRAG (NNP:[0..11] Chemosphere) (.:[11..12] .) (CD:[13..17] 1996)
        (CC:[18..25] Jul;33-LRB-) (CD:[25..26] 2) (-RRB-:[26..27] -RRB-)
        (CD:[27..31] :265) (::[31..32] -) (CD:[32..34] 76) (.:[34..35] .)))

;sentence 1 Span:41..169
;Interaction of 2,4,4'-trichloro-2'-hydroxydiphenyl ether with microsomal 
;cytochrome P450-dependent monooxygenases in rat liver.
;[56..97]:substance:"2,4,4'-trichloro-2'-hydroxydiphenyl ether"
;[115..130]:cyp450:"cytochrome P450"
;[141..155]:substance:"monooxygenases"
(SENT
  (NP-HLN
    (NP (NN:[41..52] Interaction))
    (PP (IN:[53..55] of)
      (NP (NN:[56..91] 2,4,4'-trichloro-2'-hydroxydiphenyl) (NN:[92..97] ether)))
    (PP (IN:[98..102] with)
      (NP (JJ:[103..113] microsomal)
        (ADJP
          (NML (NN:[115..125] cytochrome) (NN:[126..130] P450))
          (HYPH:[130..131] -) (JJ:[131..140] dependent))
        (NNS:[141..155] monooxygenases)))
    (PP-LOC (IN:[156..158] in)
      (NP (NN:[159..162] rat) (NN:[163..168] liver)))
    (.:[168..169] .)))

;section 2 Span:173..240
;Hanioka N, Omae E, Nishimura T, Jinno H, Onodera S, Yoda R, Ando M.
(SEC
  (FRAG (NNP:[173..180] Hanioka) (NNP:[181..182] N) (,:[182..183] ,)
        (NNP:[184..188] Omae) (NNP:[189..190] E) (,:[190..191] ,)
        (NNP:[192..201] Nishimura) (NNP:[202..203] T) (,:[203..204] ,)
        (NNP:[205..210] Jinno) (NNP:[211..212] H) (,:[212..213] ,)
        (NNP:[214..221] Onodera) (NNP:[222..224] S,) (NNP:[225..229] Yoda)
        (NNP:[230..232] R,) (NNP:[233..237] Ando) (NNP:[238..240] M.)))

;section 3 Span:244..334
;Division of Environmental Chemistry, National Institute of Health Sciences, 
;Tokyo, Japan.
(SEC
  (FRAG (NNP:[244..252] Division) (IN:[253..255] of)
        (NNP:[256..269] Environmental) (NNP:[270..279] Chemistry)
        (,:[279..280] ,) (NNP:[281..289] National) (NNP:[290..299] Institute)
        (IN:[300..302] of) (NNP:[303..309] Health) (NNP:[310..318] Sciences)
        (,:[318..319] ,) (NNP:[321..326] Tokyo) (,:[326..327] ,)
        (NNP:[328..333] Japan) (.:[333..334] .)))

;sentence 4 Span:338..519
;We studied the effects of 2,4,4'-trichloro-2'-hydroxydiphenyl ether (Irgasan 
;DP300) on the kinetics of the cytochrome P450 (P450)-dependent monooxygenases
;in  rat liver microsomes.
;[364..399]:substance:"2,4,4'-trichloro-2'-hydroxydiphenyl"
;[400..405]:substance:"ether"
;[407..421]:substance:"Irgasan  DP300"
;[446..461]:cyp450:"cytochrome P450"
;[463..467]:cyp450:"P450"
;[479..493]:substance:"monooxygenases"
(SENT
  (S
    (NP-SBJ (PRP:[338..340] We))
    (VP (VBD:[341..348] studied)
      (NP
        (NP (DT:[349..352] the) (NNS:[353..360] effects))
        (PP (IN:[361..363] of)
          (NP
            (NP (NN:[364..399] 2,4,4'-trichloro-2'-hydroxydiphenyl)
                (NN:[400..405] ether))
            (NP (-LRB-:[406..407] -LRB-)
               (NNP:[407..414] Irgasan) (NN:[416..421] DP300)
              (-RRB-:[421..422] -RRB-))))
        (PP (IN:[423..425] on)
          (NP
            (NP (DT:[426..429] the) (NNS:[430..438] kinetics))
            (PP (IN:[439..441] of)
              (NP (DT:[442..445] the)
                (ADJP
                  (NML
                    (NML (NN:[446..456] cytochrome) (NN:[457..461] P450))
                    (NML (-LRB-:[462..463] -LRB-) (NN:[463..467] P450)
                         (-RRB-:[467..468] -RRB-)))
                  (HYPH:[468..469] -) (JJ:[469..478] dependent))
                (NNS:[479..493] monooxygenases))))))
      (PP-LOC (IN:[494..496] in)
        (NP (NN:[498..501] rat) (NN:[502..507] liver)
            (NNS:[508..518] microsomes))))
    (.:[518..519] .)))

;sentence 5 Span:520..767
;The activities of 7-ethoxyresorufin O-deethylase (EROD)  and
;7-pentoxyresorufin O-depentylase (PROD) in rat liver microsomes exposed to 
;3-methylcholanthrene (MC) and phenobarbital (PB) respectively, were 
;substantially inhibited by Irgasan DP300.
;[538..568]:substance:"7-ethoxyresorufin O-deethylase"
;[570..574]:substance:"EROD"
;[581..613]:substance:"7-pentoxyresorufin O-depentylase"
;[615..619]:substance:"PROD"
;[657..677]:substance:"3-methylcholanthrene"
;[679..681]:substance:"MC"
;[687..700]:substance:"phenobarbital"
;[702..704]:substance:"PB"
;[753..766]:substance:"Irgasan DP300"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[520..523] The) (NNS:[524..534] activities))
      (PP (IN:[535..537] of)
        (NP
          (NP
            (NP (NN:[538..555] 7-ethoxyresorufin) (NN:[556..568] O-deethylase))
            (NP (-LRB-:[569..570] -LRB-) (NN:[570..574] EROD)
                (-RRB-:[574..575] -RRB-)))
          (CC:[577..580] and)
          (NP
            (NP (NN:[581..599] 7-pentoxyresorufin) (NN:[600..613] O-depentylase))
            (NP (-LRB-:[614..615] -LRB-) (NN:[615..619] PROD)
                (-RRB-:[619..620] -RRB-)))))
      (PP-LOC (IN:[621..623] in)
        (NP
          (NP (NN:[624..627] rat) (NN:[628..633] liver)
              (NNS:[634..644] microsomes))
          (VP (VBN:[645..652] exposed)
            (NP (-NONE-:[652..652] *))
            (PP-CLR (TO:[653..655] to)
              (NP
                (NP
                  (NP (NN:[657..677] 3-methylcholanthrene))
                  (NP (-LRB-:[678..679] -LRB-) (NN:[679..681] MC)
                      (-RRB-:[681..682] -RRB-)))
                (CC:[683..686] and)
                (NP
                  (NP (NN:[687..700] phenobarbital))
                  (NP (-LRB-:[701..702] -LRB-) (NN:[702..704] PB)
                      (-RRB-:[704..705] -RRB-)))))
            (ADVP (RB:[706..718] respectively))))))
    (,:[718..719] ,)
    (VP (VBD:[720..724] were)
      (ADJP-MNR (RB:[726..739] substantially))
      (VP (VBN:[740..749] inhibited)
        (NP-1 (-NONE-:[749..749] *))
        (PP (IN:[750..752] by)
          (NP-LGS (NNP:[753..760] Irgasan) (NN:[761..766] DP300)))))
    (.:[766..767] .)))

;sentence 6 Span:768..948
;The inhibition profile of EROD was  competitive, whereas that of PROD was
;noncompetitive; the Ki values from Hanes  plots were 0.24 and 1.48 microM for
;EROD and PROD, respectively.
;[794..798]:substance:"EROD"
;[833..837]:substance:"PROD"
;[862..864]:quantitative-name:"Ki"
;[895..899]:quantitative-value:"0.24"
;[904..908]:quantitative-value:"1.48"
;[909..915]:quantitative-units:"microM"
;[920..924]:substance:"EROD"
;[929..933]:substance:"PROD"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[768..771] The) (NN:[772..782] inhibition)
            (NN:[783..790] profile))
        (PP (IN:[791..793] of)
          (NP (NN:[794..798] EROD))))
      (VP (VBD:[799..802] was)
        (ADJP-PRD (JJ:[804..815] competitive))
        (,:[815..816] ,)
        (SBAR-ADV (IN:[817..824] whereas)
          (S
            (NP-SBJ
              (NP (DT:[825..829] that))
              (PP (IN:[830..832] of)
                (NP (NN:[833..837] PROD))))
            (VP (VBD:[838..841] was)
              (ADJP-PRD (JJ:[842..856] noncompetitive)))))))
    (::[856..857] ;)
    (S
      (NP-SBJ
        (NP (DT:[858..861] the) (NN:[862..864] Ki) (NNS:[865..871] values))
        (PP (IN:[872..876] from)
          (NP (NNP:[877..882] Hanes) (NNS:[884..889] plots))))
      (VP (VBD:[890..894] were)
        (NP-PRD
          (NP (CD:[895..899] 0.24)
            (NML-1 (-NONE-:[899..899] *P*)))
          (CC:[900..903] and)
          (NP (CD:[904..908] 1.48)
            (NML-1 (NN:[909..915] microM))))
        (PP (IN:[916..919] for)
          (NP (NN:[920..924] EROD) (CC:[925..928] and) (NN:[929..933] PROD)))
        (,:[933..934] ,)
        (ADVP (RB:[935..947] respectively))))
    (.:[947..948] .)))

;sentence 7 Span:949..1142
;Phenacetin  O-deethylase (PCOD) and 4-nitrophenol hydroxylase (4NPH)
;activities in rats  exposed to PB were also inhibited by Irgasan DP300, at Ki
;values lower than  those for other microsomes.
;[949..973]:substance:"Phenacetin  O-deethylase"
;[975..979]:substance:"PCOD"
;[985..1010]:substance:"4-nitrophenol hydroxylase"
;[1012..1016]:substance:"4NPH"
;[1049..1051]:substance:"PB"
;[1075..1088]:substance:"Irgasan DP300"
;[1093..1095]:quantitative-name:"Ki"
(SENT
  (S
    (NP-SBJ-2
      (NP
        (NP
          (NML
            (NML (NN:[949..959] Phenacetin) (NN:[961..973] O-deethylase))
            (NML (-LRB-:[974..975] -LRB-) (NN:[975..979] PCOD)
                 (-RRB-:[979..980] -RRB-)))
          (NML-1 (-NONE-:[980..980] *P*)))
        (CC:[981..984] and)
        (NP
          (NML
            (NML (NN:[985..998] 4-nitrophenol) (NN:[999..1010] hydroxylase))
            (NML (-LRB-:[1011..1012] -LRB-) (NN:[1012..1016] 4NPH)
                 (-RRB-:[1016..1017] -RRB-)))
          (NML-1 (NNS:[1018..1028] activities))))
      (PP-LOC (IN:[1029..1031] in)
        (NP
          (NP (NNS:[1032..1036] rats))
          (VP (VBN:[1038..1045] exposed)
            (NP (-NONE-:[1045..1045] *))
            (PP (TO:[1046..1048] to)
              (NP (NN:[1049..1051] PB)))))))
    (VP (VBD:[1052..1056] were)
      (ADVP (RB:[1057..1061] also))
      (VP (VBN:[1062..1071] inhibited)
        (NP-2 (-NONE-:[1071..1071] *))
        (PP (IN:[1072..1074] by)
          (NP-LGS (NNP:[1075..1082] Irgasan) (NN:[1083..1088] DP300)))
        (,:[1088..1089] ,)
        (PP-MNR (IN:[1090..1092] at)
          (NP
            (NP (NN:[1093..1095] Ki) (NNS:[1096..1102] values))
            (ADJP (JJR:[1103..1108] lower)
              (PP (IN:[1109..1113] than)
                (NP
                  (NP (DT:[1115..1120] those))
                  (PP (IN:[1121..1124] for)
                    (NP (JJ:[1125..1130] other) (NNS:[1131..1141] microsomes))))))))))
    (.:[1141..1142] .)))

;sentence 8 Span:1143..1247
;Irgasan DP300 slightly inhibited testosterone 6  beta-hydroxylase (TS6BH)
;activities in some microsomes.
;[1143..1156]:substance:"Irgasan DP300"
;[1176..1208]:substance:"testosterone 6  beta-hydroxylase"
;[1210..1215]:substance:"TS6BH"
(SENT
  (S
    (NP-SBJ (NNP:[1143..1150] Irgasan) (NN:[1151..1156] DP300))
    (ADVP-EXT (RB:[1157..1165] slightly))
    (VP (VBD:[1166..1175] inhibited)
      (NP
        (NML
          (NML (NN:[1176..1188] testosterone) (CD:[1189..1190] 6)
               (NN:[1192..1208] beta-hydroxylase))
          (NML (-LRB-:[1209..1210] -LRB-) (NN:[1210..1215] TS6BH)
               (-RRB-:[1215..1216] -RRB-)))
        (NNS:[1217..1227] activities))
      (PP-LOC (IN:[1228..1230] in)
        (NP (DT:[1231..1235] some) (NNS:[1236..1246] microsomes))))
    (.:[1246..1247] .)))

;sentence 9 Span:1248..1369
;No effect of Irgasan  DP300 on lauric acid omega-hydroxylase (LAOH) activity
;was evident in any  microsomal preparations.
;[1261..1275]:substance:"Irgasan  DP300"
;[1279..1308]:substance:"lauric acid omega-hydroxylase"
;[1310..1314]:substance:"LAOH"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1248..1250] No) (NN:[1251..1257] effect))
      (PP (IN:[1258..1260] of)
        (NP (NNP:[1261..1268] Irgasan) (NN:[1270..1275] DP300)))
      (PP (IN:[1276..1278] on)
        (NP
          (NML
            (NML (JJ:[1279..1285] lauric) (NN:[1286..1290] acid)
                 (NN:[1291..1308] omega-hydroxylase))
            (NML (-LRB-:[1309..1310] -LRB-) (NN:[1310..1314] LAOH)
                 (-RRB-:[1314..1315] -RRB-)))
          (NN:[1316..1324] activity))))
    (VP (VBD:[1325..1328] was)
      (ADJP-PRD (JJ:[1329..1336] evident))
      (PP-LOC (IN:[1337..1339] in)
        (NP (DT:[1340..1343] any) (JJ:[1345..1355] microsomal)
            (NNS:[1356..1368] preparations))))
    (.:[1368..1369] .)))

;sentence 10 Span:1370..1617
;These results indicated that Irgasan DP300 inhibits MC-  and PB-inducible
;P450-dependent monoxygenase in vitro competitively or  noncompetitively, and
;that the P450 enzymes of the CYP1A or CYP2B subfamily may  contribute to
;Irgasan DP300 toxicity.
;[1399..1412]:substance:"Irgasan DP300"
;[1422..1424]:substance:"MC"
;[1431..1433]:substance:"PB"
;[1444..1448]:cyp450:"P450"
;[1459..1471]:substance:"monoxygenase"
;[1530..1542]:cyp450:"P450 enzymes"
;[1550..1555]:cyp450:"CYP1A"
;[1559..1564]:cyp450:"CYP2B"
;[1594..1607]:substance:"Irgasan DP300"
(SENT
  (S
    (NP-SBJ (DT:[1370..1375] These) (NNS:[1376..1383] results))
    (VP (VBD:[1384..1393] indicated)
      (SBAR
        (SBAR (IN:[1394..1398] that)
          (S
            (NP-SBJ (NNP:[1399..1406] Irgasan) (NN:[1407..1412] DP300))
            (VP (VBZ:[1413..1421] inhibits)
              (NP
                (NP
                  (ADJP (NN:[1422..1424] MC) (HYPH:[1424..1425] -)
                    (ADJP-2 (-NONE-:[1425..1425] *P*)))
                  (ADJP-3 (-NONE-:[1425..1425] *P*))
                  (NML-4 (-NONE-:[1425..1425] *P*)))
                (CC:[1427..1430] and)
                (NP
                  (ADJP (NN:[1431..1433] PB) (HYPH:[1433..1434] -)
                    (ADJP-2 (JJ:[1434..1443] inducible)))
                  (ADJP-3 (NN:[1444..1448] P450) (HYPH:[1448..1449] -)
                          (JJ:[1449..1458] dependent))
                  (NML-4 (NN:[1459..1471] monoxygenase))))
              (ADVP (FW:[1472..1474] in) (FW:[1475..1480] vitro))
              (ADVP (RB:[1481..1494] competitively) (CC:[1495..1497] or)
                    (RB:[1499..1515] noncompetitively)))))
        (,:[1515..1516] ,) (CC:[1517..1520] and)
        (SBAR (IN:[1521..1525] that)
          (S
            (NP-SBJ
              (NP (DT:[1526..1529] the)
                 (NN:[1530..1534] P450) (NNS:[1535..1542] enzymes))
              (PP (IN:[1543..1545] of)
                (NP (DT:[1546..1549] the)
                  (NML
                    (NML (NN:[1550..1555] CYP1A)
                      (NML-1 (-NONE-:[1555..1555] *P*)))
                    (CC:[1556..1558] or)
                    (NML (NN:[1559..1564] CYP2B)
                      (NML-1 (NN:[1565..1574] subfamily)))))))
            (VP (MD:[1575..1578] may)
              (VP (VB:[1580..1590] contribute)
                (PP-CLR (TO:[1591..1593] to)
                  (NP
                    (NML (NNP:[1594..1601] Irgasan) (NN:[1602..1607] DP300))
                    (NN:[1608..1616] toxicity)))))))))
    (.:[1616..1617] .)))

;section 11 Span:1621..1665
;PMID: 8696774 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1621..1625] PMID) (::[1625..1626] :) (CD:[1627..1634] 8696774)
        (NN:[1635..1636] -LSB-) (NNP:[1636..1642] PubMed) (::[1643..1644] -)
        (NN:[1645..1652] indexed) (IN:[1653..1656] for)
        (NNP:[1657..1665] MEDLINE-RSB-)))
